COPD medications, treatment adherence remains low. 3, 11 Underlying reasons for suboptimal medication treatment of COPD are complex and include patient-related (eg, patients 0 perception of the disease), treatment-related (eg, complex regimens), and social/environmental (eg, patient-prescriber relationship) factors. 12 Understanding optimal clinical management of multimorbid individuals is further complicated by the current guidelines and clinical practice, which tend to focus on management of single conditions rather than multiple conditions faced by over half of adults with COPD. 13, 14 Recognizing the need for better management of patients with COPD and comorbid depression, in 2008, the American College of Chest Physicians and the National Institute of Mental Health jointly noted the importance of understanding how depression and its treatment may affect clinical outcomes of COPD, including treatment adherence in COPD patients. 4 Since then, much attention has focused on the role of adequate depression treatment, as evidence suggests persistent use of antidepressants is associated with improved adherence to medications used to treat chronic comorbid conditions, such as heart failure, 15 diabetes, 15, 16 and multiple sclerosis. 17 Despite these findings, it remains unclear whether treated depression exerts similar benefits to COPD medication use and adherence. Thus, understanding the effects of treating depression may prove critical to improving COPD management, reducing COPD symptoms, and preventing acute exacerbations and adverse outcomes (eg, hospitalization) for patients who suffer from COPD and comorbid depression. [18] [19] [20] This study aimed to examine whether use of and adherence to antidepressant treatment were associated with use of and adherence to COPD maintenance medications among Medicare beneficiaries with COPD and comorbid depression. 
| Study sample
The study sample consists of all beneficiaries with newly diagnosed 21 Incident depression cases were defined as those having no depression in the 6 months before the first COPD diagnosis. We measured depression using relevant ICD-9-CM codes (296.2x, 296.3x, and 311.xx) and identified cases using a diagnosis-based algorithm that includes ≥1 inpatient or ≥2 outpatient claims for depression diagnosis or ≥1 outpatient depression claim plus ≥1 antidepressant prescription fill. 17 This depression algorithm has been validated against medical charts and shown good to excellent agreement. 22 To ensure the presence of active major depression, we required beneficiaries to have evidence of depression after their first depression diagnosis. We assigned a depression index date as the time of the first major depression claim after COPD diagnosis and considered 6 months before the index date as a baseline.
Patients were excluded if, at baseline, they had (1) Patients who had ≥1 prescription fill of the studied antidepressants for their depression comorbidity were defined as antidepressant users or non-users, otherwise. Among users, adherence to antidepressants was defined as the extent to which patients take antidepressants as prescribed. 24 Medication adherence was measured using proportion of days covered (PDC), calculated as the number of days with available medications divided by the number of days at quarterly intervals. 25 We
categorized PDC values as adherent or non-adherent using a commonly used, clinically relevant cutoff of PDC ≥0.8. For any medication
Key points
• In a Medicare COPD-depression cohort, antidepressanttreated depression was associated with increased use and adherence to COPD maintenance medications, when compared with nontreated depression.
• A higher probability of COPD maintenance medication use and adherence also was observed among patients who adhered to their antidepressants than among nonadherent patients.
• Antidepressant treatment may be a key determinant to improving medication-taking behaviors among COPD patients comorbid with depression.
use and PDC, we adjusted for Part A-covered skill nursing facility or hospitalization days, as drug payment for these days is bundled under Table 1 ).
We refrained from including COPD rescue/acute medications because these medications are used pro re nata (PRN) or "as needed" and use and adherence cannot be adequately assessed for PRN medications.
| Time-dependent and time-independent covariates
Time-independent covariates measured at baseline included: sociodemographics, reason for Medicare entitlement, low-income subsidy status, and geographically based income and education level. Regional data for each patient were obtained from the Area Health Resources
Files linked to CCW Medicare beneficiary summary files through county codes. 27 The calendar year of the first COPD diagnosis, the depression index date, and baseline COPD maintenance medication use and adherence also were included in analyses.
Time-dependent confounders measured at baseline and quarterly during the follow-up included the following: health behaviors, comorbidity, COPD severity, depression severity, number of unique medications (excluding COPD and depression medications), and nursing home stay (yes/no). We measured health behaviors using the presence or absence of utilization of 3 preventive health services: pneumococcal and influenza vaccinations, colorectal cancer screening, prostate cancer screening (males), and mammography screening and/or pap smears (females) in Part B claims data. 28, 29 This measure, which ranged from 0 (unhealthy behavior) to 3 (healthier behavior), was analyzed as a categorical variable (0, 1, ≥2) due to its skewed distribution. Overall comorbidity was mea- data. [31] [32] [33] Finally, we measured whether residents resided in a longterm care facility using Part A skill nursing facility admission and discharge dates and Part B Claims.
| Statistical analysis
To account for time-varying confounders that also are intermediates between antidepressant treatment (exposures) and COPD maintenance medication use and adherence (outcomes), we adopted marginal structural models (MSMs) that use weighting strategies for balancing covariates between exposure and non-exposure. 34 MSM analysis involves 2 steps. The first step is to estimate a stabilized weight for an individual in each quarter based on inverse probability of treatment weighting (IPTW) and inverse probability of censoring weighting (IPCW). To estimate IPTW and IPCW, we fitted 2 multivariate logistic regression models, using antidepressant exposure and death as the outcome, respectively, and observed time-dependent and time-independent variables as covariates (Supplementary Table 2 ). In the second step, we incorporated the estimated stabilized weights into generalized linear models (GLMs) with a Poisson distribution and log link to estimate the effects of current quarterly antidepressant exposure on the subsequent quarter of COPD medication outcomes. 35 Generalized estimating equations (GEE) was also included in the GLMs to account for clustering of quarterly repeated measures of antidepressant exposures. 36 We reported relative ratios (RRs) and corresponding 95% con- Table 2 ).
The probability of using any COPD maintenance medication was higher among beneficiaries who were white, female, younger than 65 years old, entitled to Medicare due to elderly, or low-income subsidy recipients (Table 3) . The same characteristics, except gender, also were observed as significant factors for predicting adherence to COPD maintenance medication treatment in COPD patients with depression comorbidity. Table 4 shows the effect of adherence to antidepressants on COPD maintenance medication outcomes. Both MSM (with weights) and adjustment regression (without weights) analysis showed similar results-that is, patients who adhered to antidepressants were significantly more likely to use and adhere their COPD maintenance medications. Our results indicate that COPD patients with treated comorbid depression have a 15% higher probability of any use and 8% higher probability of regular use of their COPD maintenance medications compared to peers untreated with antidepressants. Furthermore, COPD-depression patients who adhered to their antidepressant treatment were more likely to use and adhere to their COPD maintenance medications.
Our study demonstrates the importance of regularly treating depression in initiating and maintaining COPD medication use, 2 key factors in preventing COPD exacerbations and other adverse health outcomes, including hospitalization 3 and death. 37 Our study, which repeatedly measured antidepressant treatment exposure over a maximum of 7 years, found the majority (82%) of newly diagnosed COPD-depression patients used antidepressants at least once over 7 years. Our findings from administrative data are similar to those of previous studies on antidepressant use in a prevalent and incident cohort of COPD-depression patients (81% and 70%, respectively). 32, 38 Our data, however, are higher than those of prior clinical trials 39, 40 and observational studies of COPD patients with comorbid depression. 41 These previous studies were cross sectional with small sample sizes and short follow-up times, and relied on selfreport for evidence of antidepressant use, reasons that may explain the observed discrepancy.
Our study also identified several characteristics as significant factors in predicting untreated depression, including male sex, non-white race/ethnicity, older age, no use of studied preventive services, having multiple comorbid conditions in addition to depression and COPD, and higher COPD and depression severity (see Supplementary Table 2 ). In particular, racial/ethnic differences in receiving adequate depression treatment have been documented in the literature. [42] [43] [44] Reasons responsible for such differences are multiple but include variation in access to mental health care, insurance coverage, and language and cultural background. 42 After MSM weighting analysis, black race (vs white race) remains a significant predictor of both nonuse and nonadherence to COPD maintenance medications, consistent with a major study indicating the blacks are disproportionately not adherent to prescription medications in general. 43 Interventions targeted to patients with comorbid COPD and depression with these characteristics may be warranted to reduce inadequate depression and COPD treatment.
Of particular concern is the high level of undertreatment of COPD in our COPD-depression cohort. The presence of comorbid depression has a detrimental effect on treatment and management of many chronic conditions. 47, 48 For example, patients with diabetes and depression are more likely to discontinue medication treatment, compared to patients with diabetes alone. 47, 48 However, when adequately treated, comorbid depression is associated with improved adherence to medications used to treat coronary artery disease and/or dyslipidemia, diabetes, 15 and multiple sclerosis. 17 Our study adds to the current body of knowledge by showing that antidepressant treatment may improve use of and adherence to COPD maintenance medications. One potential mechanism is that the symptoms of depression, including apathy, hopelessness, and concomitant anxiety, may be alleviated after antidepressant treatment, and improvement in depressive symptoms enhances patients 0 adoption of healthy behaviors, including regularly taking COPD medications as prescribed. Taken together, these studies emphasize the importance of treating depression and the need to improve depression care in patients with multiple chronic conditions, including COPD.
This study has notable strengths. First, we followed patients sites and/or reimbursed by non-Medicare payers (eg, the VA or out-ofpocket), as well as reflect changes in clinical practice due to the Affordable Care Act implemented in 2013. 49 In conclusion, in a Medicare COPD-depression cohort, treated depression increased use of and adherence to necessary maintenance medications for COPD. Antidepressant treatment is a key determinant that can be effectively intervened to improving COPD medication-taking behaviors among COPD patients comorbid with depression.
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